MarketCapExport financials
AnaptysBio (ANAB)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
AnaptysBio Income Statement 2026-2011 | ANAB
Brief overview of financial performance at AnaptysBio
The comparison covers a five-year financial horizon. Revenue reported by AnaptysBio was 75 million dollars at the beginning of the period and 235 million dollars at the end. The five-year change reached +212.8%, while CAGR stood at 25.6%. This pace points to rapid expansion of the business.
EBITDA was −23.3 million dollars at the beginning and 48.5 million dollars at the end of the period (+307.8%). EBITDA grew faster than revenue, indicating positive operating leverage. Comparing the endpoints gives EBITDA margins of −31.1% and 20.7%. The company improved its ability to convert sales into EBITDA.
Across the five years, the net result shifted from −19.9 million dollars to −13.2 million dollars. The negative result improved without reaching break-even.
Market capitalization changed from 587 million dollars to 1.5 billion dollars (+158.8%). The market value rose well beyond the pace of financial improvement.
Financial takeaway
The five-year financial profile is predominantly positive. The constructive conclusion rests on sales growth, positive operating leverage and improving net profitability. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement AnaptysBio
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.59 B | 1.52 B | 461 M | 629 M | 700 M | 953 M | 587 M | 393 M | 1.61 B | 2.11 B | 312 M | - | - | - | - | - |
Shares |
29 M | 28.8 M | 28.4 M | 26.9 M | 28.2 M | 27.4 M | 27.3 M | 27.1 M | 24.7 M | 19.8 M | 18.2 M | - | - | - | - | - |
Historical Prices |
54.9 | 52.8 | 16.2 | 23.4 | 24.9 | 34.8 | 21.5 | 16.2 | 63.8 | 101 | - | - | - | - | - | - |
Net Income |
131 M | -13.2 M | -145 M | -164 M | -129 M | -57.8 M | -19.9 M | -97.3 M | -61.7 M | -30.1 M | -4.26 M | -5.4 M | 3.53 M | -5.54 M | - | - |
Revenue |
53 M | 235 M | 91.3 M | 17.2 M | 10.3 M | 63.2 M | 75 M | 8 M | 5 M | 10 M | 16.7 M | 17.6 M | 15.8 M | 5.48 M | - | - |
Operating Income |
32.3 M | 227 M | 66.2 M | -164 M | -115 M | -56.8 M | -23.9 M | -107 M | -66.7 M | -28.8 M | -3.02 M | -3.32 M | - | - | - | - |
Interest Expense |
-1 K | 5.45 M | 14 K | -2 K | 12 K | 37 K | -11 K | 1.04 M | 1.65 M | 1.78 M | 458 K | 460 K | - | - | - | - |
EBITDA |
32.3 M | 227 M | 66.2 M | -164 M | -114 M | -56.2 M | -23.3 M | -107 M | -66.4 M | -28.6 M | -2.79 M | -3.05 M | 5.18 M | -4.71 M | - | - |
Operating Expenses |
20.7 M | 7.7 M | 25.1 M | 182 M | 125 M | 120 M | 98.9 M | 115 M | 71.7 M | 38.8 M | 19.7 M | 20.9 M | 11 M | 10.8 M | - | - |
General and Administrative Expenses |
23.4 M | 11.3 M | 13.6 M | 41.9 M | 36.6 M | 21.5 M | 18.9 M | 16.1 M | 15.5 M | 9.34 M | 4.29 M | 3.59 M | 2.35 M | 1.95 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement AnaptysBio
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
28.7 M | - | 27.8 M | 28.8 M | 30.6 M | 30.5 M | 28.9 M | 27.4 M | 26.8 M | 26.6 M | 26.5 M | 26.6 M | 28 M | 28.5 M | 28.3 M | 28.2 M | 27.7 M | 27.6 M | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.1 M | 27 M | 27 M | 26.9 M | 24.1 M | 23.9 M | 23.8 M | 23.8 M | 20.4 M | 20.3 M | 15.3 M | 2.65 M | 2.64 M | 2.64 M | 2.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-52.9 M | - | 15.1 M | -38.6 M | -39.3 M | - | -32.9 M | -46.7 M | -43.9 M | - | -37.3 M | -39.8 M | -44.3 M | - | -33.5 M | -32.6 M | -36.3 M | - | -6.67 M | -429 K | -18.2 M | - | -23.8 M | -21.5 M | -8.26 M | -20.3 M | -31 M | -24 M | -22.1 M | -17 M | -16 M | -13.6 M | -15.1 M | -6.86 M | -9.09 M | -2.68 M | -11.4 M | -4.58 M | -1.12 M | 2.32 M | -888 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
25.6 M | - | 76.3 M | 22.3 M | 27.8 M | - | 30 M | 11 M | 7.18 M | - | 3.32 M | 3.46 M | 1.37 M | - | 1.29 M | 1.22 M | 970 K | - | 20.9 M | 30 M | 11.2 M | - | - | - | 15 M | - | - | 5 M | - | - | 5 M | - | - | - | - | 7 M | - | - | 3.21 M | 5.85 M | 4.87 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-34.6 M | - | 34.7 M | -26.2 M | -27.5 M | - | -22.8 M | -40.3 M | -42.2 M | - | -37.7 M | -40.1 M | -44.4 M | - | -29.6 M | -27.8 M | -31.7 M | - | -6.76 M | -533 K | -18.4 M | - | -24.3 M | -22.6 M | -10.3 M | -22.3 M | -33.7 M | -26.7 M | -24.8 M | -19.7 M | -16.9 M | -14.4 M | -15.8 M | -7.15 M | -9.09 M | -2.56 M | -9.99 M | -3.17 M | -1.08 M | 2.36 M | -1.14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-1 K | - | - | 3.53 M | 1.9 M | - | -5 K | - | -2 K | - | 1 K | 3 K | -4 K | - | 4 K | 6 K | 6 K | - | 33 K | - | 3 K | - | - | - | - | - | 240 K | 281 K | 320 K | - | 400 K | 436 K | 451 K | - | 452 K | 439 K | 428 K | - | 116 K | 116 K | 115 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-34.5 M | - | - | - | -27.4 M | - | - | - | -42 M | - | - | - | -44.2 M | - | -29.1 M | -27.5 M | -31.6 M | - | -6.31 M | -248 K | -18.2 M | - | -23.9 M | -22.4 M | -10.1 M | -22.3 M | -33.4 M | -26.4 M | -24.7 M | -19.7 M | -16.7 M | -14.3 M | -15.7 M | -7.15 M | -8.95 M | -2.46 M | -9.95 M | -3.17 M | -900 K | 2.48 M | -1.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
60.2 M | - | 41.6 M | 48.4 M | 55.3 M | - | 52.8 M | 51.3 M | 49.4 M | - | 41 M | 43.6 M | 45.8 M | - | 30.9 M | 29 M | 32.7 M | - | 27.7 M | 30.6 M | 29.6 M | - | 24.3 M | 22.6 M | 25.3 M | - | 33.7 M | 31.7 M | 24.8 M | - | 21.9 M | 14.4 M | 15.8 M | - | 9.09 M | 9.56 M | 9.99 M | - | 4.29 M | 3.49 M | 6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
26.2 M | - | 10.2 M | 10.6 M | 14.1 M | - | 10.6 M | 9.3 M | 12.3 M | - | 10.2 M | 10.7 M | 10.8 M | - | 8.86 M | 8.17 M | 10.2 M | - | 5.43 M | 5.25 M | 5.42 M | - | 4.79 M | 4.69 M | 4.28 M | - | 3.81 M | 4.31 M | 4.14 M | - | 4 M | 3.83 M | 3.95 M | - | 2.39 M | 2.35 M | 2.05 M | - | 1.01 M | 1.15 M | 1.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company AnaptysBio (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
Russia